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The lung is not usually included in the list of organs that might be affected by type 2 diabetes (T2D). However, its abundance of collagen and elastin fibres, 
crucial proteins in the extracellular matrix, together with its vascularization reach, make the lung parenchyma a potential target for chronic hyperglycaemia [1]. 
Indeed, cross-sectional studies conducted during the past few decades have shown that adults with T2D have lower forced vital capacity (FVC) and forced 
expiratory volume in the first second (FEV1) than adults without T2D [2]. A few pathophysiological mechanisms have also been well documented, including 
insulin and leptin resistance, low-grade chronic inflammatory status, microvascular lung damage and autonomic neuropathy [1]. 
However, little is known of the potential relationship between advanced glycation end-products (AGEs) and lung function, and what scarce information there is 
has been focused on patients with chronic obstructive pulmonary disease (COPD), in which higher skin AGE deposition and plasma AGE concentrations have 
been reported [3]. Yet, the relationship between AGEs and pulmonary function, taking into account the presence of glucose abnormalities, has not been 
previously examined. For this reason, skin AGE accumulation and spirometric manoeuvres were assessed in a large population with no known pulmonary 
disease according to the presence of glucose abnormalities.  
Both our control and prediabetes populations were recruited from a total of 1924 Caucasian subjects enrolled between July 2015 and May 2017 into the 
ILERVAS project (ClinTrials.gov Identifier: NCT03228459). This ongoing randomized interventional study is concerned with early diagnosis of subclinical 
vascular and ‘hidden’ kidney diseases [4]. Inclusion criteria were: age between 45–70 years; no history of cardiovascular disease or T2D; and at least one 
cardiovascular risk factor (obesity, hypertension, dyslipidaemia, smoking or first-degree relative with premature cardiovascular disease). Exclusion criteria 
were: COPD; T2D; chronic kidney disease; active neoplasia; life expectancy < 18 months; pregnancy; and darker skin colour (Fitzpatrick scale types > 5).  
Smokers who had stopped smoking ≥ 1 year prior to recruitment were considered former smokers. Prediabetes was diagnosed in 34.6% (n = 660) of subjects 
according to American Diabetes Association criteria [glycosylated haemoglobin (HbA1c): 39–47 mmol/mol or 5.7–6.4%]. Also, 79 age-matched T2D patients 











were recruited from the outpatients diabetic clinic of University Hospital Arnau de Vilanova in July 2017. Informed consent was obtained from all participants, 
and the protocol was approved by the Arnau de Vilanova University Hospital ethics committee.  
Anthropometric data were obtained by standardized protocols. Glycosylated haemoglobin was determined using the cobas b 101® system (Roche Diagnostics 
International, Rotkreuz, Switzerland). Dry samples of capillary blood were used for analyses of values of total cholesterol and serum creatinine.  
Forced spirometry was performed using a portable ultrasonic spirometer (Sibelmed DATOSPIR, Sibel S.A., Barcelona, Spain). Subjects were required to 
have at least three reproducible measurements, and the output with the highest total FEV1 and FVC scores was used for analyses. Various spirometric 
parameters were measured as a percentage of predicted values. ‘Normal’ FEV1 was defined as a value ≥ 80% of that predicted, a ‘non-obstructive 
ventilatory defect’ as an FVC < 80% of predicted value with an FEV1/FVC ratio ≥ 70%, and an ‘obstructive ventilatory defect’ as an FEV1/FVC ratio < 70%, 
as per criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).  
Skin autofluorescence (AF) was measured on the left forearm using the AGE Reader™ (DiagnOptics, Groningen, Netherlands), a fully automated, non-
invasive, non-operator-dependent desktop device that uses ultraviolet A (UVA) spectrum wavelengths. The mean AF value of three readings, expressed in 
arbitrary units (AU), was recorded. The same device was used for measurements in all participants.  
Normally distributed variables were evaluated using the Shapiro–Wilk test. Given their skewed distribution, quantitative data were expressed as medians 
(interquartile range, IQR). Comparisons between groups were made using the Mann–Whitney U test or Pearson’s chi-squared test, and the relationship 
between continuous variables was assessed by Spearman’s correlation test.  
Accuracy of skin AF as a measurement of interest to discriminate patients with FEV1 scores ≤ 80% of predicted from normal cases was evaluated using 
receiver operating characteristic (ROC) curve analysis and a complete sensitivity/specificity report. In addition, comparisons between area under the ROC 
(AUROC) of skin AF and HbA1c were performed using the Hanley and McNeil test.  











Stepwise multivariate regression analysis explored the variables independently associated with FVC and FEV1, including age, gender, body mass index 
(BMI), tobacco use (number of pack-years), HbA1c and skin AF. Statistical significance was accepted at the level of P < 0.05. All statistical analyses were 
performed using IBM SPSS Statistics for Windows, version 20.0, software (IBM Corp., Armonk, NY, USA). 
The main clinical characteristics of the study population are shown in Table I. Skin AF was significantly higher in patients with T2D than in those with either 
prediabetes [2.5 (2.0–3.0) vs 1.9 (1.7–2.2) AU; P < 0.001] or no glucose abnormalities [1.9 (1.7–2.2) AU; P < 0.001]. No differences in skin AF levels were 
observed between the latter two groups. In addition, patients with T2D showed significantly lower FEV1 and FVC scores, and a greater prevalence of FEV1 
scores < 80% than either prediabetes or non-diabetes subjects (Table S1; see supplementary materials associated with this article online). Those with 
prediabetes showed significantly lower FVC scores than those with no glucose abnormalities (P = 0.046). 
When skin AGE deposition was evaluated according to ventilatory pattern, patients with respiratory (non-obstructive or obstructive) defects exhibited 
significantly increased skin AF in comparison to subjects with normal pulmonary function (all P < 0.001). When the entire study population was evaluated, 
positive correlations were found between skin AF and age, HbA1c, tobacco packs/year and estimated glomerular filtration rate (eGFR) on univariate analysis 
(Table S2; see supplementary materials associated with this article online). In addition, a significant but negative correlation between skin AF and pulmonary 
parameters, such as FVC (r = -0.114, P < 0.001) and FEV1 (r = -0.212, P < 0.001), was observed. Moreover, these correlations became even stronger when 
only T2D patients were analyzed (FVC: r = -0.453, P < 0.001; FEV1: r = -0.393, P < 0.001).  
 ROC analysis revealed that the optimal cut-off point for skin AF was 2.05 AU: at this point, the AUROC was 0.614 (0.582–0.646), with a sensitivity of 53.5% 
and specificity of 63.3% (Fig. 1). The percentage of subjects with FEV1 < 80% increased from 17.4% in those with skin AF < 2.05 AU to 27.6% in those with 
skin AF ≥ 2.05 AU (P < 0.001). These data indicate a twofold greater risk of having an abnormal FEV1 (mean difference: 1.9, 95% CI: 1.5–2.3; P < 0.001) 
compared with subjects with lower skin AF values. In addition, skin AF significantly improved the AUROC curve obtained with HbA1c measurement [0.614 











(0.582–0.646) vs 0.555 (0.521–0.589); P = 0.014]. Furthermore, stepwise multivariate regression analysis revealed that skin AF (along with gender, BMI, 
tobacco use and HbA1c) was independently associated with predicted measures of FEV1 (R2 = 0.121) and FVC (R2 = 0.122) (Table S3; see supplementary 
materials associated with this article online).  
To the best of our knowledge, this is the first-ever study of subjects without pulmonary disease to demonstrate that skin AGE deposition is related to a 
decrease in spirometric values and a larger percentage of abnormal ventilatory patterns. In addition, this negative association was more aggravated among 
patients with T2D. 
AGE formation increases with age and is accelerated by chronic hyperglycaemia, chronic inflammation and oxidative stress [5]. Skin AF is also associated 
with several clinical variables (for example, age, creatinine clearance), lifestyle factors (smoking status, coffee consumption), and genetic polymorphisms [6]. 
Our present data from a large population are in concordance with those findings. As AGEs are mainly irreversibly linked to tissue proteins, its accumulation is 
greater with slow turnover rates, as seen in subcutaneous tissue, lens and cartilage [5,6]. 
Similar to other cross-sectional studies, our present study has shown how patients with T2D exhibit a 13% decrease in FEV1 and 14% decrease in FVC of a 
theoretical value compared with non-diabetes subjects [1, 2]. On this basis, it has been suggested that non-enzymatic glycosylation of pulmonary 
parenchymal proteins and chest wall cartilage may favour the development of less-compliant lung parenchyma and, thus, limit chest mobility, an underlying 
factor in the restrictive respiratory pattern described in T2D [1]. Our results, with skin AF as an independent risk factor for spirometric values, support the 
potentially deleterious impact of AGEs on pulmonary function. 
The role of AGEs in the genesis and rapid progression of both macro- and microvascular chronic T2D complications has been suggested previously [7]. 
Likewise, descriptions of messenger RNA (mRNA) expression of AGE receptor (RAGE) by type-II alveolar epithelial cells are worthy of attention [8]. Indeed, 
AGE–RAGE interactions in the lungs might trigger pathophysiological cascades, leading to impaired pulmonary function through lung endothelial cell 











dysfunction, proinflammatory effects and cell apoptosis [8]. It is also worth mentioning that our data revealed that prediabetes has a negative impact on FVC 
in comparison to subjects with normal glucose metabolism but similar skin AF. This finding suggests that mechanisms (such as insulin resistance) other than 
AGE accumulation might be playing a primary role in initiating the lung impairment seen in T2D.   
The involvement of AGEs in patients with COPD has also been previously evaluated, and skin AF was significantly higher in 202 patients with mild-to-very-
severe COPD compared with 193 old and young healthy controls [3]. Similar results were also observed in a smaller group of patients, with skin AF proving to 
be a negative determinant of FEV1 even after adjusting for age, gender and pack-years of smoking [9]. In fact, our present study demonstrates that the 
negative correlation between skin AF and pulmonary function is not restricted to COPD, as the association was stronger among patients with T2D than in non-
diabetes subjects.  
Nevertheless, our study has a few limitations. First, it would have been of interest to compare skin AF data with plasma AGE concentrations. Second, as skin 
AF mainly provides information on AGEs linked to fluorescent proteins, the role of other compounds was not evaluated and, third, the cross-sectional nature of 
the study does not permit causality to be established.  
In conclusion, the present study has provided the first clinical evidence that, in people with no known pulmonary disease, AGEs, as measured by skin AF, are 
correlated with a decline in spirometric values. The link was even stronger among patients with T2D, suggesting that the accumulation of AGEs in lung 
parenchyma and the chest wall may now be added to the mechanisms involved in the deleterious effects of T2D on lung function.  
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Figure legend  
 
Fig. 1. Receiver operating characteristic (ROC) curve analysis was used to evaluate the accuracy of HbA1c and skin autofluorescence (AF) as a 
measurement of interest to discriminate between disease cases [patients with forced expiratory volume in the first second (FEV1) < 80% of predicted 
value] and normal cases, together with a sensitivity/specificity report for the entire study population. Total area under the ROC curve value was interpreted 
as: 0.9–1.0, excellent; 0.8–0.9, good; 0.7–0.8, fair; 0.6–0.7, poor; and 0.5–0.6, not useful. 
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Table I. Main clinical characteristics, metabolic data, pulmonary function and breathing pattern parameters in the study population according to glucose 
abnormalities 
 T2D patients Prediabetes Non-T2D patients 
n 79 660 1170 
Women, n (%) 39 (49.4) 393 (59.5) 567 (48.5) 
Age (years) 61 (55–65) 59 (54–64) 57 (52–62) 
Known T2D duration (years) 12 (8–15) – – 
Body mass index (kg/m2) 30.8 (27.8–35.6) 29.6 (26.9–33.2) 28.1 (25.3–31.4) 
Current smoker, n (%) 18 (22.7) 155 (23.4) 387 (33.0) 
Tobacco (n, pack-years) 21.0 (15.0–42.8) 20.9 (10.1–34.8) 20.5 (9.0–32.0) 
HbA1c (%) 8.4 (6.7–9.6) 5.8 (5.7–6.0) 5.4 (5.2–5.5) 
HbA1c (mmol/mol) 67 (50–81) 40 (39–42) 36 (33–37) 
Total cholesterol (mg/dL) 185 (159–213) 203 (182–229) 201 (180–227) 
eGFR (mL/min/1.73 m2) 90.0 (74.7–94.9) 95.8 (85.9–101.9) 97.1 (87.7–103.3) 
Skin autofluorescence (AU) 2.5 (2.0–3.0) 1.9 (1.7–2.2) 1.9 (1.7–2.2) 
Data are expressed as medians (IQR) or as n (%); 
T2D: type 2 diabetes; eGFR: estimated glomerular filtration rate by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 
 
Table S1. Main pulmonary function parameters and breathing patterns in the study population according to glucose abnormalities (GAs) 











 T2D patients With GAs Without GAs P* P** 
n 79 660 1170 – – 
FEV1 (% predicted) 82 (74–97) 93 (82–106) 95 (83–106) < 0.001 < 0.001 
FVC (% predicted) 80 (68–91) 92 (81–103) 94 (83–103) < 0.001 < 0.001 
FEV1/FVC 82 (74–85) 79 (75–83) 79 (74–83) 0.061 0.020 
FEV1 < 80% predicted, n (%) 35 (44.3) 135 (20.5) 211 (18.0) < 0.001 < 0.001 
Non-obstructive ventilatory 
defect,a n (%) 
32 (40.5) 127 (19.2) 186 (15.9) < 0.001 < 0.001 
Obstructive ventilatory 
patterna, n (%) 
11 (13.9) 74 (11.2) 129 (11.0) 0.475 0.429 
Data are expressed as medians (IQR) or as n (%);  
* T2D vs prediabetes; ** T2D vs normal glucose metabolism;  
T2D: type 2 diabetes; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; a as per Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) 
 











Table S2. Correlation of skin autofluorescence (AF) with clinical characteristics, metabolic data 1 
and pulmonary parameters 2 
 Skin AF 
 r P 
Age (years) 0.232 < 0.001 
T2D duration (years) -0.120 0.423 
Body mass index (kg/m2) -0.004 0.854 
Tobacco use (n, pack-years) 0.277 < 0.001 
HbA1c (% or mmol/mol) 0.086 < 0.001 
eGFR (mL/min/1.73 m2) -0.156 < 0.001 
FEV1 (% predicted) -0.212 < 0.001 
FVC (% predicted) -0.114 < 0.001 
FEV1/FVC -0.103 < 0.001 
T2D: type 2 diabetes; HbA1c: glycosylated haemoglobin; eGFR: estimated glomerular filtration 3 
rate by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; FVC: forced 4 
vital capacity; FEV1: forced expiratory volume in the first second 5 
6 












Table S3. Stepwise multivariate regression analysis of variables associated with forced vital 6 
capacity (FVC) and forced expiratory volume in the first second (FEV1) 7 
  β B (95% CI) P 
FEV1 (% predicted) Gender (male/female) 0.139 4.944 (2.968 to 6.950) < 0.001 
 HbA1c (%) -0.092 -2.675 (-4.295 to -1.056) 0.001 
 Skin autofluorescence (AU) -0.102 -3.739 (-5.875 to -1.602) 0.001 
 Body mass index (kg/m2) -0.116 -0.400 (-0.591 to -0.209) < 0.001 
 Tobacco use (n, packs-year) -0.200 -0.195 (-0.252 to -0.138) < 0.001 
 Age (years)  -0.027 – 0.356 
R2 = 0.121 Constant – – < 0.001 
FVC (% predicted) Gender (male/female) 0.180 6.231 (4.276 to 8.187) < 0.001 
 Skin autofluorescence (AU) -0.076 -2.741 (-4.823 to -0.659) 0.010 
 HbA1c (%) -0.103 -2.923 (-4.501 to -1.344) < 0.001 
 Tobacco use (n, packs-year) -0.117 -0.111 (-0.166 to -0.056) < 0.001 
 Body mass index (kg/m2) -0.187 -0.630 (-0.816 to -0.443) < 0.001 
 Age (years)  -0.054 – 0.061 
R2 = 0.122 Constant – – < 0.001 
HbA1c: glycosylated haemoglobin 8 
 9 
 10 
